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Successful Treatment of Vancomycin-Resistant Enterococcus Ventriculitis in a Child
Paulo Sérgio Lucas da Silva, Henrique Monteiro Neto and Lílian Márcia Sejas
Pediatric Intensive Care Unit, Department of Pediatrics, State Hospital of Diadema, Federal University of São Paulo; São Paulo, SP, Brazil
Enterococci are an uncommon cause of CNS infection. A 20 month-old boy, diagnosed with hydrocephalus with
ventriculoperitoneal shunt and history of lengthy hospitalization and use of wide spectrum antibiotics, was admitted
to the pediatric intensive care unit diagnosed with ventriculitis. On the 14th day of empirical antibiotic therapy
(vancomycin and meropenem) the child presented fever while the CSF sample culture evidenced vancomycin-
resistant Enterococcus faecium. The patient received intravenous linezolid achieving cerebrospinal fluid sterilization.
Conclusion: Intravenous linezolid appears to be a safe and effective therapy for vancomycin-resistant enterococcus
ventriculoperitoneal shunt infection.
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Enterococci are known for causing urinary tract infection,
infections of surgical wounds, nosocomial bacteremia,
infectious endocarditis and, rarely, central nervous system
infections [1]. Over the past decade, enterococcus has
become a significant nosocomial pathogen, particularly given
their resistance to multiple antimicrobial agents, and thus
represents a challenge due to the limited therapeutic options
available [2].
Only a few studies [3-9] have reported the use of linezolid
in the treatment of central nervous system infection by
vancomycin-resistant enterococcus (VRE), and only one case
reported a pediatric patient [4]. The present study described
treatment of ventriculitis caused by vancomycin-resistant
enterococcus in an infant with multiple comorbidities.
Case Report
A 20 month-old boy, with underlying diagnosis of
neurodevelopmental delay and hydrocephalus with
ventriculoperitoneal shunt (VPS) secondary to Pneumococcus
meningitis at 6 months of life, presented a cardiorespiratory
arrest on his arrival in hospital, and was then resuscitated
over 23 minutes. The infant remained hospitalized for 10 days
within the pediatric intensive care unit (PICU), diagnosed with
aspirative pneumonia and cardiogenic shock, receiving
oxacillin and ceftriaxone.
On the 18th day, the patient was readmitted to the PICU
with a diagnosis of septic shock due to central venous
catheter-related infection, being discharged from the PICU on
the 7th day, having received vancomycin and cefepime for a
total of 3 weeks. On the 39th day he was readmitted to the PICU
diagnosed with ventriculitis. The cerebrospinal fluid (CSF)
sample obtained by reservoir puncture revealed 71 cells/mm3
(72% neutrophils; glucose 13 mg/dL and protein 69 mg/dL).
Cultures were negative. The patient received external
ventricular drain associated with vancomycin and meropenem
empirically for 4 weeks, undergoing a VPS on the 30th PICU
day. On the 14th postoperative (PO) day, the patient developed
perivalvular abscess, the CSF obtained from the shunt
reservoir presented 74 cells/mm3 (79% neutrophils), upon
which the patient was submitted to external ventricular shunt
(EVS) whilst vancomycin and meropenem were resumed. On
the 6th PO day after EVS, fluconazole was associated due to
the presence of yeast in a routine CSF sample. Cultures for
fungus were negative. On the 14th day of antibiotic therapy,
the patient evolved with fever (39ºC), presenting the following
laboratorial exams: white blood cells (WBC) 23,000/mm3,
platelets 156,000/mm3, C-reactive protein 20 mg/dL, CSF with
15 cells (90% neutrophils), glucose 45 g/dL, protein 910 g/dL,
Gram stain showed Gram-positive cocci in chains, and 2 serial
CSF cultures yielded Enterococcus faecium resistant to
vancomycin, ampicillin, streptomycin, ciprofloxacin,
chloramphenicol and susceptible to gentamicin. The
vancomycin minimum inhibitory concentration (MIC) of this
isolate was > 32 µg/mL (using an E-test method with an
inoculum density of 0.5 McFarland standard). Based on this
information, he was switched to linezolid monotherapy, dosed
at 10 mg/kg intravenously every 8 hours.
Following the 2nd day of linezolid, the patient became
afebrile, and after the 3rd day had sterile CSF. Following 4-
week treatment with linezolid, the patient had a new VPS in
place (CSF: 1 cell/mm3, glucose 54 g/dL and protein 90 g/dL)
and C-reactive protein of 1.78 mg/dL. Treatment continued
for a further 2 weeks, during which time CSF samples remained
sterile. Concentrations of linezolid in CSF were not recorded.
The patient tolerated the 6-week treatment without showing
evidence of bone marrow suppression. Fecal cultures
obtained during treatment with linezolid were negative. The
patient evolved requiring ventilation assistance due to
neurologic compromise, and was cared for in an intermediate
care unit.
Discussion
The emergence of nosocomially acquired vancomycin-
resistant enterococci has become a significant concern and a
treatment challenge to physicians [3]. Approximately 12% to
18% of enterococci in the United States exhibit vancomycin
resistance [3].
www.bjid.com.br
298 BJID 2007; 11 (April)
Risk factors for vancomycin-resistant enterococcus (VRE)
colonization in children include young age, use of invasive
devices, antimicrobial drug administration, immunosuppression,
low birth weight, and underlying malignancy [10]. Such patients
have commonly been treated with vancomycin or broad-
spectrum antibiotics before VRE isolation [11]. Two important
factors predisposing patients to VRE infection are the
percentage of hospital days receiving antimicrobial therapy of
any type and the number of days receiving intravenous
vancomycin [7]. Our patient had received several weeks of broad-
spectrum antibiotics before developing VRE meningitis; this
prolonged use of antibiotics, associated with the long stay in
hospital were likely contributory factors in both colonization
and subsequent infection with VRE. However, treatment with
lengthy courses of broad-spectrum antibiotics is often
unavoidable in critically ill patients.
The National Nosocomial Infections Surveillance system
of the Centers for Disease Control and Prevention reported
vancomycin resistance in 28.5% of nosocomial enterococcal
intensive care unit infections in 2003 [12]. In a recent study,
14% of VRE-colonized patients progressed to infection
within 15 days of a positive surveillance culture [13]. A recent
review noted that, although Enterococcus faecalis is
responsible for 80% of enterococcal infections, E. faecium
strains account for 98% of vancomycin-resistant cases [14].
There are no established guidelines for the treatment of
central nervous system infection caused by VRE.
Therapeutic options for vancomycin-resistant enterococci
are limited because these organisms are usually resistant to
multiple antimicrobial agents. Treatment often has to include
investigational drugs or less tested new drugs. In our patient
the therapy included intravenous linezolid. To the best of
our knowledge, there has only been 1 previous case report
of ventriculitis due to enterococcus in a child treated
successfully with linezolid [4].
Linezolid, the first member of the oxazolidinones class of
antibiotics licensed by the U.S. Food and Drug
Administration (FDA), inhibits bacterial protein synthesis
by binding to the 50S ribosomal subunit. It is approved for
use in adults and children for serious infections caused by
Enterococcus faecium or Enterococcus faecalis including
vancomycin-resistant strains (VRE), Staphylococcus aureus
including methicilllin-resistant strains (MRSA), coagulate-
negative staphylococci and streptococci including penicillin-
resistant Streptococcus pneumoniae [15]. Linezolid is
essentially bacteriostatic. In vitro time-kill experiments
against multidrug-resistant (including vancomycin-resistant)
enterococci, linezolid was not bactericidal but had greater
bacteriostatic activity against these organisms [16].
CSF penetration of linezolid suggests utility in treatment
of meningitis and intracranial prosthetic device infections.
In individuals with noninflamed meninges, linezolid
concentrations in CSF were 70% of plasma concentrations
[17]. In adults, reversible thrombocytopenia is the major
hematologic consequence of linezolid use, generally
occurring after ≥ 2 weeks of treatment and thought to be due
to transient bone marrow suppression. In children,
thrombocytopenia is less common; however, a complete
blood count should be monitored weekly while children are
receiving linezolid [17]. In adults, linezolid-induced
neuropathy has been reported among patients receiving the
drug for > 6 months.
Vancomycin and aminoglycosides with variable
penetration of the blood-brain barrier and monitoring CSF
levels is recommended. Intraventricular administration of
antimicrobials with irregular penetration of blood-brain
barrier makes theoretical sense but is controversial [18].
Problems with intraventricular antibiotics include allergic
reactions, drug-induced inflammation and toxic or
inadequate concentrations [18]. Even though our case
presented gentamycin-susceptible enterococcus, the
patient was successfully treated without needing
intraventricular administration of drugs.
Optimal management of ventricular shunt infection
requires removal of the shunt, placement of a temporary
external ventricular drain (EVD), followed by reinternalization
after CSF sterilization. A recent analysis strongly confirmed
this as the most effective treatment method [19].
Length of time on antibiotic therapy in patients with
ventriculoperitoneal shunt infection remains controversial.
Studies employing linezolid for the treatment of VPS
infections range from 3 to 12 weeks in length [4,8,20,21].
Despite receiving prolonged treatment, our patient presented
no bone marrow compromise according to serial hemograms.
However, peripheral neuropathic signs could not be assessed
in this case because the patient presented severe neurologic
compromise due to the underlying disease and comorbidity.
In conclusion, intravenous linezolid appears to be a safe and
effective therapy for vancomycin-resistant enterococcus
ventriculitis. Our success with linezolid in this instance is
encouraging for the future role of this class of drugs for the
treatment of shunt infections.
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